دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: An evidence-based approach to the categories of primary and secondary prevention
Edoardo Mannucci MD | Giovanni Antonio Silverii MD
doi : 10.1111/dom.15226
The ‘Behavioral Balance Model’: A new perspective on the aetiology and therapy of obesity
Bernd Schultes MD 1 | Barbara Ernst PhD 1 | Manfred Hallschmid PhD 2,3,4 | Marco Bueter MD 5,6 | Sebastian M. Meyh?fer MD
doi : 10.1111/dom.15271
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months
Kristina S. Boye PhD 1 | Jérémie Lebrec PhD 2 | Anne Dib MD 1 | Elke Heitmann PhD 1 | Marco Orsini Federici PhD 1 | Maria Yu MS 1 | Hélène Sapin MSc 1 | Annabel Barrett MA 1 | Bruno Guerci MD 3 | Francesco Giorgino MD 4 | Martin Füchtenbusch MD 5 | Luis-Emilio Garc?a-Pérez PhD
doi : 10.1111/dom.15145
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes
Francesco Giorgino MD 1 | Bruno Guerci MD 2 | Martin Füchtenbusch MD 3 | Jérémie Lebrec PhD 4 | Kristina Boye PhD 5 | Marco Orsini Federici PhD 5 | Elke Heitmann PhD 5 | Anne Dib MD 5 | Maria Yu MS 5 | Hélène Sapin MSc 5 | Luis-Emilio Garc?a-Pérez MD
doi : 10.1111/dom.15244
Patient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: Cross-sectional surveys
Stewart B. Harris MD 1 | Kamel Mohammedi MD 2 | Monica Bertolini MD 3 | Maureen Carlyle MPH 4 | Valery Walker MSc 4 | Fang Liz Zhou MD 3 | John E. Anderson MD 5 | Jochen Seufert MD
doi : 10.1111/dom.15240
Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom
Wajd Alkabbani PhD 1 | Baiju R. Shah MD 2,3 | Arsène Zongo PhD 4 | Dean T. Eurich PhD 5 | Mhd Wasem Alsabbagh PhD 1 | John-Michael Gamble PhD
doi : 10.1111/dom.15241
Impact of sarcosine on diabetic retinopathy: Findings based on weighted gene co-expression network analysis and machine learning techniques
Mingzhu Che MD 1 | Zhezheng Xia MD 1 | Depeng Jiang PhD 2 | Yanan Wang MD 1 | Hui Wang MD 1 | Yuxin Chen MD 1 | Ziyi Wang MD 1 | Yang Chen BS 1 | Xinlv Zhang BS 1 | Zejie Zhang MD 1 | Chengnan Guo MD 1 | Xiaoyu Zhang PhD 1 | Chao Zheng PhD 3 | Guangyun Mao PhD
doi : 10.1111/dom.15243
Pharmacogenetics of sodium-glucose co-transporter-2 inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker
Simeon I. Taylor MD 1 | Hua-Ren Cherng MD 2 | Zhinous Shahidzadeh Yazdi MD 1 | May E. Montasser PhD 1 | Hilary B. Whitlatch MD 1 | Braxton D. Mitchell PhD 1 | Alan R. Shuldiner MD 1 | Elizabeth A. Streeten MD 1 | Amber L. Beitelshees PharmD
doi : 10.1111/dom.15246
Impact of patient characteristic factors on the dynamics of liver glucose metabolism: Evaluation of multiparametric imaging with dynamic whole-body 18F-fluorodeoxyglucose-positron emission tomography
Kai Tonda MD 1 | Yu Iwabuchi MD 1 | Tohru Shiga MD 2 | Yoshiki Owaki RT 3 | Arashi Fujita RT 3 | Takehiro Nakahara MD 1 | Ryosuke Sakurai MD 1 | Atsushi Shimizu MD 1 | Yoshitake Yamada MD 1 | Masahiro Okada MD 4 | Masahiro Jinzaki MD
doi : 10.1111/dom.15247
Beta-cell death and dysfunction drives hyperglycaemia in organ donors
Iestyn M. Shapey PhD 1,2 | Angela Summers BSc (Hons) 1,2 | James O'Sullivan BSc 3 | Catherine Fullwood PhD 1,4 | Neil A. Hanley MBChB 1 | John Casey MBChB 5 | Shareen Forbes MBChB 5,6 | Miranda Rosenthal PhD 7 | Paul R. V. Johnson MBChB 8 | Pratik Choudhary MBBS 9 | James Bushnell MD 10 | James A. M. Shaw MBChB 11 | Daniel Neiman PhD 12 | Ruth Shemer PhD 12 | Benjamin Glaser MD 13 | Yuval Dor PhD 12 | Titus Augustine MS 1,2 | Martin K. Rutter MD 1,14 | David van Dellen MD
doi : 10.1111/dom.15248
Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)
Daisuke Yabe MD 1,2,3 | Kosuke Shiki MSc 4 | Gosuke Homma PhD 5 | Thomas Meinicke MD 6 | Yuji Ogura PhD 4 | Yutaka Seino MD 1,7 | EMPA-ELDERLY Investigators
doi : 10.1111/dom.15249
A multicomponent health care intervention is associated with improved glycaemic control in subjects with poorly controlled type 2 diabetes compared with routine care: The INTEGRA study
Angels Moll o MD 1 | Bogdan Vlacho PharmD 1,2 | M?nica Gratac?s MD 1 | Manel Mata-Cases MD 1,2 | Esther Rubinat RN 2,3,4,5 | Anna Berenguera Oss o PsyD 6,7,8 | Francesc Xavier Cos MD 1,9 | Josep Franch-Nadal MD 1,2 | Kamlesh Khunti MD 10 | D?dac Mauricio MD 1,2,11,12 | the INTEGRA research group
doi : 10.1111/dom.15250
Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials
Minji Sohn PhD 1 | Juan P. Frias MD 2 | Soo Lim MD
doi : 10.1111/dom.15251
Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real-world setting: A prospective, observational post-marketing study
Lixin Guo MD 1 | Li Li MD 2 | Qiurong Yu MD 3 | Na Wang MD 4 | Jun Chen MD 5 | Yue Xi MD 6 | Huan Wang MD 7 | Yihua Wang MD 7 | Jiawei Xu PhD
doi : 10.1111/dom.15252
Interrupting prolonged sitting with frequent short bouts of light-intensity activity in people with type 1 diabetes improves glycaemic control without increasing hypoglycaemia: The SIT-LESS randomised controlled trial
Matthew D. Campbell PhD 1,2,3 | Anwar M. Alobaid MSc 4,5 | Mark Hopkins PhD 4 | Paddy C. Dempsey PhD 3,6,7,8 | Sam M. Pearson MD 2 | Noppadol Kietsiriroje MD 2,9 | Rachel Churm PhD 10 | Ramzi A. Ajjan MD
doi : 10.1111/dom.15254
Association between glycated haemoglobin and the risk of chronic obstructive pulmonary disease: A prospective cohort study in UK biobank
Mengyao Li MB 1 | Yanan Wan MM 2 | Zheng Zhu PhD 2 | Pengfei Luo MM 2 | Hao Yu PhD 2 | Jian Su MM 1,2 | Dong Hang PhD 1 | Yan Lu MM 3 | Ran Tao PhD 1,2 | Ming Wu PhD 1,2 | Jinyi Zhou MM 1,2 | Xikang Fan PhD
doi : 10.1111/dom.15255
Association between weight loss and health care resource utilization in adults living with obesity: Evidence from a UK primary care database
Chris Bojke PhD 1 | Silvia Capucci MSc 2 | Christiane Lundegaard Haase PhD 2 | Niels V?ver Hartvig PhD 2 | Kasper Sommer Matthiessen MSc 2 | Camilla S. Morgen PhD 2 | Adriana Rendon MD 2 | Jonathan Pearson-Stuttard FRSPH
doi : 10.1111/dom.15256
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)
Surya Panicker Rajeev MD 1,2 | Carl Alexander Roberts PhD 3 | Emily Brown MBChB 1,2 | Victoria S. Sprung PhD 2,4 | Jo A. Harrold PhD 3 | Jason C. G. Halford PhD 5 | Andrej Stancak PhD 3 | Emma J. Boyland PhD 3 | Graham J. Kemp PhD 6 | Julie Perry 7 | Elaine Howarth MSc 7 | Richard Jackson MSc 7 | Andrew Wiemken MPH 8 | Richard Schwab MD 8 | Daniel J. Cuthbertson PhD 1,2 | John P. H. Wilding FRCP
doi : 10.1111/dom.15257
Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study)
Tomohiko Kimura MD 1,2 | Yukino Katakura MD 1 | Masashi Shimoda MD 1 | Fumiko Kawasaki MD 3 | Mizuho Yamabe MD 4 | Fuminori Tatsumi MD 1 | Michihiro Matsuki MD 5 | Yuichiro Iwamoto MD 1 | Takatoshi Anno MD 3 | Yoshiro Fushimi MD 1 | Shinji Kamei MD 6 | Yukiko Kimura MD 2,3 | Shuhei Nakanishi MD 1 | Tomoatsu Mune MD 1 | Kohei Kaku MD 3 | Hideaki Kaneto MD 1 | COMING study Group
doi : 10.1111/dom.15258
Efficacy and safety of once-weekly versus once-daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis
Paschalis Karakasis MD 1 | Dimitrios Patoulias PhD 2,3 | Konstantinos Pamporis MD 4 | Djordje S. Popovic PhD 5 | Panagiotis Stachteas MD 1 | Konstantinos I. Bougioukas PhD 4 | Nikolaos Fragakis PhD 1 | Manfredi Rizzo PhD
doi : 10.1111/dom.15259
Diabetes foot complications and standardized mortality rate in type 2 diabetes
Mike Stedman MSc 1 | Adam Robinson MD 2 | George Dunn MA 3 | Bernado Meza-Torres PhD 4 | J. Martin Gibson PhD 2,5 | Neil D. Reeves PhD 6 | Edward B. Jude MD 5 | Michael Feher PhD 7 | Gerry Rayman MD 8 | Martin B. Whyte PhD 9,10 | Michael Edmonds PhD 9 | Adrian H. Heald DM
doi : 10.1111/dom.15260
Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial
Linong Ji MD 1 | Jinmiao Lu PhD 2,3 | Leili Gao MD 1 | Changjiang Ying MD 4 | Jiao Sun MD 5 | Jie Han MS 6 | Wenhua Zhao MS 7 | Yunming Gao MS 8 | Kun Wang MD 9 | Xin Zheng MD 10 | Daosheng Xie MS 11 | Juping Ding MS 2 | Jiahong Zhao MD 2 | Qiang Yu PhD 2 | Tong Wang PhD
doi : 10.1111/dom.15261
Younger patients and low c-peptide immunoreactivity index but not nutritional states affect fasting blood ketone levels in Japanese with type 1 diabetes after sodium-glucose cotransporter 2 inhibitor administration
Hanako Nakajima MD 1 | Hiroshi Okada MD 1 | Yuta Yoshimura MD 2 | Toru Tanaka MD 3 | Goji Hasegawa MD 4 | Kazuteru Mitsuhashi MD 5 | Noriyuki Kitagawa MD 6 | Takuro Okamura MD 1 | Yoshitaka Hashimoto MD 7 | Takafumi Senmaru MD 1 | Emi Ushigome MD 1 | Naoko Nakanishi MD 1 | Masahiro Yamazaki MD 1 | Masahide Hamaguchi MD 1 | Michiaki Fukui MD
doi : 10.1111/dom.15262
Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial
Weimin Wang MD 1 | Xin Yan MMSc 2 | Zhifeng Cheng MD 3 | Qiqi Zhang PhD 4 | Rui Wang MD 4 | Yuying Deng MD 4 | Jianhua Ma MD 5 | Dalong Zhu MD
doi : 10.1111/dom.15263
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German–Austrian diabetes registry
Julia Brandts MD 1,2 | Sascha R. Tittel MSc 3,4 | Peter Bramlage MD 5 | Thomas Danne MD 6 | Johanna M. Brix MD 7,8 | Stefan Zimny MD 9 | Christoph H. J. Heyer MD 10 | Reinhard W. Holl MD 3,4 | Dirk Müller-Wieland MD
doi : 10.1111/dom.15264
Clinical evaluation of a decision support system for glucose infusion in hypoglycaemic clamp experiments
Jacopo Pavan PhD 1 | David Herzig PhD 2 | Afrodity Tripyla MD 2 | Chiara Dalla Man PhD 1 | Lia Bally MD 2 | Simone Del Favero PhD
doi : 10.1111/dom.15265
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes
Thomas R. Pieber MD 1 | Marisse Asong MD 2 | Gabriele Fluhr MD 1 | Vera H?ller MD 1 | Niels R. Kristensen PhD 2 | Jonas H. Larsen MSc 3 | Rasmus Ribel-Madsen PhD 2 | Eva Svehlikova MD 1 | Siri Vinther PhD 2 | Margarete Voortman MSc 1 | Hanne Haahr PhD
doi : 10.1111/dom.15266
The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial
Jie Yu PhD 1,2,3 | Arianne N. Sweeting PhD 1,4,5 | Chris Gianacas MBiostat 1,6 | Lauren Houston PhD 1,7 | Vivian Lee PhD 1,2 | Robert A. Fletcher MSc 1 | Vlado Perkovic PhD 1,2 | Qiang Li MBiostat 1 | Brendon L. Neuen PhD 1 | Otavio Berwanger PhD 8 | Hiddo J. L. Heerspink PhD 1,9 | Dick de Zeeuw PhD 9 | Clare Arnott PhD
doi : 10.1111/dom.15267
Severe (level 3) hypoglycaemia occurrence in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States)
Alexandria Ratzki-Leewing PhD 1,2 | Jason E. Black MSc 2 | Anna R. Kahkoska MD 3 | Bridget L. Ryan PhD 1,2 | Guangyong Zou PhD 1,4 | Neil Klar PhD 1 | Kristina Timcevska BMSc 2 | Stewart B. Harris MD
doi : 10.1111/dom.15268
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial
Emily R. Hankosky PhD 1 | Hui Wang PhD 2 | Lisa M. Neff MD 1 | Hong Kan PhD 1 | Fangyu Wang MS 1 | Nadia N. Ahmad MD 1 | Adam Stefanski MD 1 | W. Timothy Garvey MD
doi : 10.1111/dom.15269
Metformin restores prohormone processing enzymes and normalizes aberrations in secretion of proinsulin and insulin in palmitate-exposed human islets
Quan Wen PhD 1 | Azazul Islam Chowdhury PhD 1 | Banu Aydin MD 1 | Mudhir Shekha PhD 1,2 | Rasmus Stenlid PhD 1,3,4 | Anders Forslund MD 1,3,4 | Peter Bergsten PhD 1
doi : 10.1111/dom.15270
Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials
Mehmet Kanbay MD 1 | Sidar Copur MD 2 | Dimitrie Siriopol MD 3 | Abdullah Burak Yildiz MD 2 | Abduzhappar Gaipov MD 4 | Daniel H. van Raalte MD 5 | Katherine R. Tuttle MD
doi : 10.1111/dom.15272
Derivation and independent validation of kidneyintelX.dkd: A prognostic test for the assessment of diabetic kidney disease progression
Girish N. Nadkarni MD 1,2,3 | Sharon Stapleton PhD 4 | Dipti Takale MSc 5 | Katherine Edwards PhD 4 | Kara Moran PhD 4 | Gohar Mosoyan MSc 1 | Michael K. Hansen PhD 6 | Michael J. Donovan PhD 4 | Hiddo J. L. Heerspink PhD 7 | Fergus Fleming BSc 4 | Steven G. Coca DO
doi : 10.1111/dom.15273
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy
Linong Ji MD 1 | Jinmiao Lu PhD 2,3 | Leili Gao MD 1 | Xiaoguang Yan MD 4 | Jifang Li MM 5 | Zhifeng Cheng MD 6 | Lili Zhang MD 7 | Junhang Tian MM 8 | Ping Li MM 9 | Jie Bai MM 10 | Daosheng Xie MS 11 | Jiahong Zhao MD 2 | Juping Ding MS 2 | Qiang Yu PhD 2 | Tong Wang PhD
doi : 10.1111/dom.15274
Continuous glucose monitoring metrics and pregnancy outcomes in insulin-treated diabetes: A post-hoc analysis of the GlucoMOMS trial
Doortje Rademaker MD 1,2 | Anne W. T. van der Wel MD 1 | Rik van Eekelen PhD 1 | Daphne N. Voormolen PhD 3 | Harold W. de Valk PhD 4 | Inge M. Evers PhD 5 | Ben Willem Mol PhD 6,7 | Arie Franx PhD 8 | Sarah E. Siegelaar PhD 9,10 | Bas B. van Rijn PhD 8 | J. Hans DeVries PhD 9 | Rebecca C. Painter PhD 2,11 | GlucoMOMS studygroup
doi : 10.1111/dom.15276
Long-term effects of coronavirus disease 2019 on diabetes complications and mortality in people with diabetes: Two cohorts in the UK and Hong Kong
Eric Yuk Fai Wan PhD 1,2,3 | Sukriti Mathur BSc 3 | Ran Zhang MPH 3 | Athene Hoi Ying Lam MBBS 3 | Boyuan Wang MPH 3 | Vincent Ka Chun Yan BPharm 1 | Celine Sze Ling Chui PhD 2,4,5 | Xue Li PhD 1,2,6 | Carlos King Ho Wong PhD 1,2,3 | Francisco Tsz Tsun Lai PhD 1,2 | Ching Lung Cheung PhD 1,2 | Esther Wai Yin Chan PhD 1,2,7,8 | Kathryn Choon Beng Tan MD 6 | Ian Chi Kei Wong PhD
doi : 10.1111/dom.15279
Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins
Wei Chen PhD 1 | Jia Lu PhD 2 | Leona Plum-M?rschel MD 3 | Grit Andersen MD 3 | Eric Zijlstra PhD 3 | Anshun He PhD 1 | Tian Xie MS 1 | Longling Li PhD 1 | Chunyue Hao PhD 1 | Zhongru Gan PhD 1 | Tim Heise MD
doi : 10.1111/dom.15281
Effects of 8 weeks of aerobic endurance training on functional capacity and metabolic variables in people with type 1 diabetes: A secondary outcome analysis of the ULTRAFLEXI-1 study
Alexander Müller MSc 1 | Othmar Moser PhD 1,2 | Christoph Sternad MD 1 | Faisal Aziz PhD 1 | Christina Unteregger MSc 1 | Harald Kojzar BSc 1 | Ines Mursic MD 1 | Caren Sourij MD 3 | Peter Pferschy MSc 1 | Norbert Tripolt PhD 1 | Felix Aberer MD 1 | Harald Sourij MD
doi : 10.1111/dom.15245
Longitudinal association of continuous glucose monitoring-derived metrics with cognitive decline in older adults with type 2 diabetes: A 1-year prospective observational study
Taiki Sugimoto PhD 1,2 | Haruhiko Tokuda MD 3,4,5 | Hisayuki Miura MD 5,6 | Shuji Kawashima MD 5 | Takuya Omura MD 4,5 | Takafumi Ando PhD 7 | Yujiro Kuroda PhD 1 | Nanae Matsumoto PhD 1 | Kosuke Fujita PhD 1 | Kazuaki Uchida MS 1,8 | Yoshinobu Kishino MD 1,9 | Takashi Sakurai MD
doi : 10.1111/dom.15275
Daily unstructured physical activity affects mean glucose, occurrence of hypoglycaemia and glucose variability in people with type 1 diabetes
Linda C. A. Drenthen MD 1 | Mandala Ajie MSc 1 | Esmée A. Bakker PhD 2,3 | Evertine J. Abbink PhD 1 | Dick H. J. Thijssen PhD 2,4 | Cees J. Tack PhD 1 | Bastiaan E. de Galan PhD
doi : 10.1111/dom.15277
Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal–bolus insulin in UK clinical practice
Melanie J. Davies CBE 1,2 | Amra Ciric Alibegovic MD 3 | Pranav Kelkar PhD 3 | Uffe Christian Braae PhD 3 | Anders Boeck Jensen PhD
doi : 10.1111/dom.15278
Time in range in patients with type 2 diabetes who are long-term users of d-Nav®, an artificial intelligence-driven technology for autonomous titration of insulin dosing
Kevin J. Williams MD 1 | Eran Bashan PhD 2 | Caitlin Kruse 2 | Sajitha Sritharan 2 | Israel Hodish MD
doi : 10.1111/dom.15280
